Despite the undisputed rise in the generic pharmaceutical market in recent years, it has been near-impossible to measure accurately the value of the market consistently across countries.
IMS Health has been working with the industry to devise a new international standard to make measurement of the generics market comprehensive, comparable and reliable. Find out more here.
IMS Generic Market Analyzer incorporates this new definition in one easy-to-use database covering 10 global markets, which enables you to define and measure the unprotected market by categorizing the market into branded, company branded and INN unbranded products. It clearly differentiates between generics and off patent brands, allowing you to quickly and easily analyze market values and volumes over the last four years for each of these segments.
